Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 25 of the 39 sources its claims cite were checked for support.
Abstract
Background: Obesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), have led to significant weight loss among users. Digital health platforms offering behavioral support may enhance the effectiveness of these medications. Objective: This retrospective service evaluation investigated the impact of engagement with an app-based digital weight loss program on weight loss outcomes among individuals using GLP-1 receptor agonists (semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (tirzepatide) in the United Kingdom over 5 months. Methods: Data were collected from the Voy weight loss digital health platform between February 2023 and August 2024. Participants were adults aged 18-75 years with a BMI ≥30 or ≥27.5 kg/m2 with the presence of obesity-related comorbidities who initiated a weight management program involving semaglutide or tirzepatide. Engagement was defined based on attendance at coaching sessions, frequency of app use, and regular weight tracking. Participants were categorized as “engaged” or “nonengaged” accordingly. Weight loss outcomes were assessed over a period of up to 5 months. Statistical analyses included chi-square tests, independent t tests, Kaplan-Meier survival analysis, and calculations of Cohen d for effect sizes. Results: A total of 57,975 participants were included in the analysis, with 31,407 (54.2%) classified as engaged and 26,568 (45.8%) as nonengaged. Engaged participants achieved significantly greater weight loss at each time point. At month 3, engaged participants had a mean weight loss of 9% (95% CI 9% to 9.1%) compared with 5.9% (95% CI 5.9% to 6%) in nonengaged participants (P<.001), representing a mean difference of 3.1 percentage points (95% CI 3.1% to 3.1%). A Cohen d effect size of 0.89 indicated a large effect. At month 5, engaged participants had a mean weight loss of 11.53% (95% CI 11.5% to 11.6%) compared with 8% (95% CI 7.9% to 8%) in the nonengaged participants (P<.001). A Cohen d effect size of 0.56 indicated a moderate effect. Participants using tirzepatide achieved more significant weight loss than those using semaglutide at month 5 (13.9%, 95% CI 13.5% to 14.3% vs 9.5%, 95% CI 9.2% to 9.7%; P<.001). The proportion of engaged participants achieving ≥5%, ≥10%, and ≥15% weight loss was significantly higher than the nonengaged group at corresponding time points from months 3 to 5 respectively (P<.001). Conclusions: Engagement with a digital weight management platform significantly enhances weight loss outcomes among individuals using GLP-1 receptor agonists. The combination of pharmacotherapy and digital behavioral support offers a promising strategy to promote the supported self-care journey of individuals seeking clinically effective obesity management interventions.
Overview
CoChat Summary
TL;DR
In a retrospective service evaluation of 57,975 UK adults using semaglutide or tirzepatide on the Voy digital weight-loss platform, engaged participants lost significantly more weight than nonengaged participants at every time point. Engagement was associated with greater mean weight loss and higher odds of reaching ≥5%, ≥10%, and ≥15% thresholds, but the study is observational and limited by selection bias, self-reported weights, and short follow-up.
Key findings
- Of 57,975 participants, 31,407 (54.2%) were engaged and 26,568 (45.8%) were nonengaged. At month 3, engaged participants had mean weight loss of 9% (95% CI 9% to 9.1%) versus 5.9% (95% CI 5.9% to 6%) in nonengaged participants (P<.001; difference 3.1 percentage points; Cohen d=0.89). At month 5, engaged participants had mean weight loss of 11.53% (95% CI 11.5% to 11.6%) versus 8% (95% CI 7.9% to 8%) (P<.001; Cohen d=0.56).
- Participants using tirzepatide achieved greater month 5 weight loss than those using semaglutide: 13.9% (95% CI 13.5% to 14.3%) versus 9.5% (95% CI 9.2% to 9.7%) (P<.001).
- Engaged participants had significantly higher odds of achieving ≥5% weight loss at all assessed time points, ≥10% from month 2 onward, and ≥15% at months 3 and 4. For example, at month 3 the OR for ≥5% weight loss was 4.01 (95% CI 3.27-4.91; P<.001). Kaplan-Meier analyses showed significant differences; at month 4, 49.3% of engaged participants had not achieved ≥5% weight loss versus 69.8% of nonengaged participants (P<.001).
- Engagement decreased over time, with 3622 (6.3%) engaged participants remaining at month 5.
Methods
- Retrospective 2-arm service evaluation using data from the Voy digital health platform between February 2023 and August 2024. Participants were UK adults aged 18-75 years with BMI ≥30 kg/m² or ≥27.5 kg/m² with obesity-related comorbidities who initiated a weight management program involving semaglutide or tirzepatide, with up to 5 months of follow-up.
- Engagement was the primary exposure, defined as meeting any one of: attended ≥1 weight coaching session, tracked weight ≥1 per week in the app, or logged into the app for features other than only weight logging at least once. Participants were classified as engaged or nonengaged. The primary outcome was percentage weight change from baseline.
- Analyses included descriptive statistics, chi-square tests (Fisher exact when n<5), independent t tests, Kaplan-Meier survival analysis with log-rank tests, and Cohen d effect sizes. A sensitivity analysis used a subset of 1864 participants with complete baseline data and multivariable linear regression adjusting for age, gender, baseline weight, BMI category, type 2 diabetes, high cholesterol, and high blood pressure. Analyses used R version 4.3.1 with P<.05.
Limitations
- The paper states potential selection bias because participants who chose to engage may have higher motivation or health literacy; unmeasured confounding; attrition bias from reduced participant numbers over time; missing data on key variables; and self-reported weight measurements that may introduce reporting bias.
- The paper states the absence of a randomized control group limits causal inference, the 5-month follow-up may not capture long-term weight maintenance, and the predominantly female and White British/Irish population limits generalizability. It also notes the 1864-participant subset may not be representative and that smartphone/tablet access and monthly subscription fees may exclude lower socioeconomic or older adults.
- Evident from the text: the binary engaged/nonengaged classification collapses variation in engagement intensity, so dose-response relationships are not assessed; the paper acknowledges future tiered analyses could examine low, moderate, or high engagement.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
19 Valid · 1 Not valid · 8 Not checked · 59 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Behavioral factors critically influence the success of weight loss interventions [13].”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Introduction > Background
What the sources say
- Supportedcites [13] source
The Conclusions state that behavioral and psychological factors are closely related to weight loss success and may help explain differences in outcomes. The Biology-Driven Behavioral Factors section also reports that behavioral adherence predicts reductions in body weight. (LLM, conf=0.92)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This incorporation of evidence-based behavior change techniques, such as goal setting, action planning, and problem-solving, is associated with improved weight loss outcomes [47].”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Discussion > Comparison With Prior Work
What the sources say
- Partly supportedcites [47] sourceExperimental — accuracy not yet measured
The taxonomy defines goal setting (section 6), action planning (section 7), and barrier identification/problem solving (section 8) as behaviour change techniques; it even uses losing weight as an example of an outcome goal. It does not report that incorporating these techniques is associated with improved weight-loss outcomes. Searches for that association found definitions and references, not a finding about weight loss. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This limitation is partly due to complex physiological adaptations that occur in response to weight loss, including metabolic slowdown and increased appetite, which traditional interventions may not adequately address [7].”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Introduction > Background
What the sources say
- Supportedcites [7] source
The Summary says that adaptations after diet-induced weight loss include decreased energy expenditure and increased appetite, promoting weight regain. Translation to the clinic says behavioural approaches do not address the physiological controls that promote regain, making long-term maintenance difficult. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This approach potentially enhances the effectiveness of pharmacological treatments through ongoing support and education using real-time microlearning approaches to promote individual self-care capability [18], as well as through supporting the adoption of health-seeking self-care behaviors using nudges and personalized insights delivered using an accessible digital platform [19,20].”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Introduction > Background
What the sources say
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
The review does support the general part of the claim: Background (p. 2) and Key findings (p. 7) describe microlearning as person-centred content delivered in bite-size fragments that build knowledge over time, and the Conclusion (p. 9) states it 'can positively influence cognitive self-care capabilities'. But nothing in our copy attributes to microlearning an enhancement of the effectiveness of pharmacological treatments; the closest statement is the abstract's that microlearning can improve actual self-care behaviours 'when combined with monitoring such as tracking daily medicine intake', which is about monitoring, not drug efficacy. Indeed Key findings (p. 7) says the opposite for the relevant self-care pillar — microlearning 'was not effective in improving the rational use of products and services among individuals, such as compliance' — and Measurement of self-care outcomes (p. 5) reports only 4 of 11 behaviour studies (including medical adherence) reaching significance. The 'real-time' framing is also not the review's own terminology. (LLM, conf=0.78)
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
The Results (section 3.1) describe personalized text messages providing education and motivation, and the Discussion (section 4) describes text and call support as useful for maintaining motivation during weight-loss interventions. Our copy does not establish that this support enhances pharmacological treatments, or describe it as real-time microlearning that promotes individual self-care capability. (LLM, conf=0.82)
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
The Background (page unavailable) says lifestyle interventions provide guidance in self-regulation skills, which supports the general idea of helping people manage their own health behaviors. It does not say that ongoing education or real-time microlearning enhances pharmacological treatments; searches for those terms found no supporting passage. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, existing literature is limited, as the integration of digital platforms with pharmacological therapy for weight loss has yet to be extensively researched due to its novelty [28-30].”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Introduction > Background
What the sources say
- Not checked — no full text of the sourcecites [28] source
- Supportedcites [29] source
The Introduction (Background; page not provided) says only one published study had examined a remotely delivered weight-management service involving weight-loss medication. The Abstract (Background; page not provided) describes limited real-world evidence for this type of digital intervention, and the Discussion (Principal Findings; page not provided) calls the pharmacotherapy novel. Together, these support the citing sentence’s broad characterization of an emerging, under-researched approach. (LLM, conf=0.88)
- Partly supportedcites [30] sourceExperimental — accuracy not yet measured
The Discussion (Comparison With Prior Work; page not provided) says that evaluating pharmacotherapy embedded in digital weight-management interventions is still needed, supporting the claim that evidence on the combination is limited. The Introduction (Background; page not provided) describes a recently announced pilot, but the paper does not explicitly attribute the limited research to the approach’s novelty. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
30 more claims · 3 with their cited sources checked
Create a free account to see all 87 claims and to verify the 2 references still open.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 38
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Discussion > Comparison With Prior Work
“nearly 70% of our engaged participants reached this milestone by month 5.”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Results > Weight Loss Outcomes
“| 5 | 2664 (61.0) | 1705 (39.0) | 69 (37) | 117 (62.9) | 2.65 (1.96-3.59) | <.001 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| | | Thyroid | 135 (7.2) | 135 (7.2) | 114 (6.1) | 114 (6.1) | 114 (6.1) | 21 (1) | 21 (1) |”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Results > Participant Characteristics
Reported 1 · recomputed 6.104651
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Abstract > Results
“At month 5, engaged participants had a mean weight loss of 11.53% (95% CI 11.5% to 11.6%)”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Results > Engagement Levels
“| | Yes | 11.50 (11.49-11.57) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Results > Weight Loss Outcomes
“nonengaged participants had a mean weight loss of 2.9% (95% CI 2.9% to –2.9%)”
§ Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study > Results > Engagement Levels
“| | No | 2.87 (2.86-2.88) |”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“The theoretical foundations of digital interventions are grounded in established behavior change models such as the transtheoretical model and self-determination theory [39], emphasizing self-efficacy, intrinsic motivation, and readiness to change [40].”
Cited work 10.1186/s12889-023-16194-6 · retracted 2026-08-08 · notice 10.1186/s12889-026-28854-4 · this paper published 2025-03-31
Citations
Cites
1 retracted
RETRACTED ARTICLE: Tools for measuring individual self-care capability: a scoping review
El-Osta, A., Sasco, E. R., Barbanti, E., Webber, I., Alaa, A., Karki, M., Asmar, M. L. E., Idriss, H., Almadi, M., Massoud, F., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-16194-6 · Cited by 29 · cited 1×
“The theoretical foundations of digital interventions are grounded in established behavior change models such as the transtheoretical model and self-determination theory [39], emphasizing self-efficacy, intrinsic motivation, and readiness to change [40].”
Self-citationRetractedRyan, R. M., & Deci, E. L. (2000) · American Psychologist · doi:10.1037//0003-066x.55.1.68 · Cited by 54,599
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Our study, however, underscores the use of tirzepatide in a remote setting, yielding superior weight loss outcomes relative to semaglutide as evidenced in clinical trials [54,55].”
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Does tailoring matter? Meta-analytic review of tailored print health behavior change interventions
Noar, S. M., Benac, C. N., & Harris, M. S. (2007) · Psychological Bulletin · doi:10.1037/0033-2909.133.4.673 · Cited by 2,136 · cited 1×
“This is likely because personalized behavioral support provided through coaching and tailored feedback also addresses individual barriers and facilitators to weight loss, further enhancing motivation and self-efficacy [45].”
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
How are habits formed: modelling habit formation in the real world
Lally, P., van Jaarsveld, C. H. M., Potts, H. W. W., & Wardle, J. (2010) · European Journal of Social Psychology · doi:10.1002/ejsp.674 · Cited by 2,036 · cited 1×
“Regular engagement with the app may also facilitate the formation of automatic healthy behaviors through repetition and reinforcement, as suggested by habit formation theory [50].”
Michie, S., Ashford, S., Sniehotta, F. F., Dombrowski, S. U., Bishop, A., & French, D. P. (2011) · Psychology & Health · doi:10.1080/08870446.2010.540664 · Cited by 1,756 · cited 1×
“This incorporation of evidence-based behavior change techniques, such as goal setting, action planning, and problem-solving, is associated with improved weight loss outcomes [47].”
Research works printed but not linked: 2
- El-Osta, A, 2019, SelfCare, 10, 38
- Dobbs, R, 2014, Overcoming obesity: an initial economic analysis
Cited by
Bays, H. E., Toth, P. D., Alkhouri, N., Pullman, J. R., Freilich, B., Neutel, J., Ji, S., Stubbe, S., Hedges, P., & Lian, B. (2026) · Obesity · doi:10.1002/oby.70106 · Cited by 15
Johnson, H. H., Clift, A. K., Reisel, D., & Huang, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70244 · Cited by 7
“11 This definition was designed to capture meaningful, sustained engagement rather than minimal platform use.”
Self-citationTan, S. Y. T., Sng, G. G. R., & Lee, P. C. (2025) · JMIR Formative Research · doi:10.2196/78289 · Cited by 4
“Other studies have demonstrated the utility of various digital coaching platforms for patients on GLP1RA therapy for the treatment of obesity or diabetes [15,16].”
Johnson, H. H., Clift, A. K., Reisel, D., & Huang, D. R. (2025) · Journal of Medical Internet Research · doi:10.2196/83718 · Cited by 6
“These services may address critical barriers to obesity treatment, including limited health care provider time, accessibility challenges, and inadequate behavioral support [5-7].”
Self-citationChung, M., Willis, E., & Applequist, J. (2025) · Journal of Advertising · doi:10.1080/00913367.2025.2593673 · Cited by 3
“Regardless of paid promotion, user-generated content on social media of GLP-1 medications and word-of-mouth are rampant (Johnson et al. 2025).”
Hu, C., Lv, Z., Zhu, J., Lai, C., Guo, D., Chen, M., Cheng, X., Rao, M., Zhou, X., & Su, L. (2025) · Journal of Medical Internet Research · doi:10.2196/65868 · Cited by 4
“It emphasizes breaking the cycle of avoidance or inactivity often associated with obesity, replacing these behaviors with structured, rewarding actions like regular PA, healthy eating, and consistent self-monitoring [28].”
Toliver, J. C., Divino, V. M., Ng, C. D., & Wang, J. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03325-1 · Cited by 8
“%) among patients who did not use these platforms ( P < 0.001) [21].”
InfluentialExploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Adam, S., Ibrahim, F. M., Dabou, E. A. R., Pitre, S., Aiman, R., & AbdelSamad, S. (2025) · Healthcare · doi:10.3390/healthcare13233102 · Cited by 4
“Women reported higher self-efficacy than men, consistent with the literature showing stronger engagement with health-promoting behaviors among women in structured weight management [16,17].”
Clift, A. K., Reisel, D., Johnson, H. H., Sattar, N. A., & Huang, D. R. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag177 · Cited by 5
“This was defined a priori by the study team (18).”
Self-citationFarley, B., Radetich, E., D’Alessandro, J. S., & Bulaj, G. W. (2025) · Healthcare · doi:10.3390/healthcare13243220 · Cited by 2
“For cardiometabolic conditions, the clinical and financial successes of semaglutide, dulaglutide, liraglutide, and tirzepatide incentivize pharma and digital health companies to combine GLP1RAs with digital health applications [128–130].”
Sikorska, L. M., Liu, V. N., Johnson, H., Chaudry, E., Reisel, D., Clift, A. K., & Huang, D. R. (2026) · Cureus · doi:10.7759/cureus.102817
Self-citationFrom BMI to Biology: Advancing the Science of Obesity
Elsherif, M., & Elsherif, Y. S. I. A. N. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014540 · Cited by 1
Digital Augmentation of Glucagon-Like Peptide-1 for Obesity Management: Retrospective Study
Davey, B., Dabash, O., Khanna, R., Cornell, P. Y., & Huckvale, K. (2026) · Journal of Medical Internet Research · doi:10.2196/100728
Obesity: A Global Systems Disease in Transition – Narrative Review
Rangasamy, S., & Dasari, P. (2025) · Journal of Multidisciplinary Health and Innovative Technology · doi:10.4103/jmhit.jmhit_35_25
Mahaboob, L., Shehab, A., Buraiki, H. A. A., Iblasi, A. S., & Farghaly, W. K. T. (2026) · Romanian Medical Journal · doi:10.37897/rmj.2026.2.12
“Discontin-uation may be associated with partial reversal of cardiometabolic improvements achieved during active treatment [8].”
Digital health technologies in obesity: trajectory, emerging hotspots, and future perspectives
Zhang, Q., Huang, J., Mao, F., Wang, Y., Liu, W., & Peng, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1875769 · Cited by 1
“This indicates that modern digital intervention strategies have transcended the singular goal of body-mass index reduction, instead comprehensively integrating metabolic syndrome indica-tors—such as blood pressure, glucose metabolism, and lipid pro-files—into the core evaluation framework (20, 21).”
Krupski, A., Marusza, M., Stielow, V., & Zatyka, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5425
Talay, L., Xu, C., Alderete, J., Hom, J., Tan, M., & Ahuja, N. (2026) · Diabetes, obesity and metabolism · doi:10.1111/dom.71181
Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care
Cozma-Petruț, A. P., Gherghel, M., Banc, R., Tișa, I. B., Stanciu, O., Coldea, T. E., Mudura, E., Miere, D., & Filip, L. A. (2026) · Nutrients · doi:10.3390/nu18162691 · Cited by 1
“Furthermore, AI-driven tools are increasingly being explored as ad-juncts to incretin-based pharmacotherapy, offering the potential to tailor nutritional support to the specific metabolic and gastrointestinal challenges associated with GLP-1 and dual GIP/GLP-1 receptor agonist treatment [177,178].”
Talay, L., Xu, C., Hom, J., Swinckels, L., Tan, M. J., Alderete, J. D., & Ahuja, N. K. (2026) · Medicina · doi:10.3390/medicina62091647
“Consequently, healthcare scholars have begun investigating the explicit relationship between digital application engagement patterns and clinical weight loss outcomes [10,11].”
Bodner, E., Gentz, A., Wiencke, K., Mehl, N., & Schlögl, H. (2026) · Obesity Reviews · doi:10.1111/obr.70221
Cook, G. (2026) · Journal of Medical Internet Research · doi:10.2196/104227
“Real-world cohorts pairing app-based services with GLP-1 or GLP-1–gastric inhibitory polypeptide therapy report larger losses among more engaged users but share the same confounding biases previously discussed [37].”
Exploring the impact of adult obesity in Spain: Insights from a systematic literature review
Redondo‐Antón, J., Díaz-Cerezo, S., Artime, E., Santos, M. R., & Rubio, M. Á. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100334
“Patient engagement significantly influenced weight management for PwO [85,86].”
Metadata
- Authors
- Johnson, H., Huang, D., Liu, V., Ammouri, M. A., Jacobs, C., & El-Osta, A.
- Affiliations
- University of Bristol (GB)
- Menwell Limited (GB)
- Imperial College London (GB)
- Corresponding author
- Johnson, Hans
- Venue
- Journal of Medical Internet Research
- Publisher
- JMIR Publications Inc.
- Published
- 2025-03-31
- Volume
- 27
- Pages
- e69466
- ISSN
- 1438-8871 (ISSN-L)
- PMC
- PMC11997532
- OpenAlex
- W4408044046
- Cited by
- 27
- References
- 57
- Citations by year
- 2026: 18 · 2025: 9
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Medical Internet Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute for Health and Care Research
- Department of Health and Social Care
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- digital health engagement, obesity treatment, weight loss, GLP-1 receptor agonists, semaglutide, tirzepatide, GIP/GLP-1 receptor agonist, mobile health apps, behavioral support, weight monitoring, medication adherence, weight management interventions, obesity-related comorbidities, weight loss outcomes, United Kingdom
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adolescent, Adult, Aged, Glucagon-Like Peptides, Female, United Kingdom, Humans, Male, Middle Aged, Obesity, Receptors, Gastrointestinal Hormone, Retrospective Studies, Weight Loss, Treatment Outcome, Glucagon-Like Peptide 1, Young Adult, Weight Reduction Programs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.